Viking Therapeutics Rebounds After Mixed Phase 2 Weight Loss Drug Results

BTCC / BTCC Square / Global Cryptocurrency /

Author:

Release Time:

2025-08-20 18:51:01

BTCCSquare news:

Viking Therapeutics shares surged nearly 10% in early trading, recovering from yesterday's sharp decline following the release of phase 2 trial data for its oral weight loss drug VK2735. The biotech's stock had initially fallen due to concerns about the drug's safety profile, with a 20% discontinuation rate from adverse effects—double that of Eli Lilly's competing orforglipron in phase 3 trials.

Market analysts suggest the sell-off was overblown given Viking's earlier phase 1 results showed better tolerability and the current trial's smaller 280-patient sample size. The oral formulation's convenience advantage over injectable alternatives maintains its commercial potential, with speculation growing about potential acquisition interest from larger pharmaceutical companies.

By:

Log in to Reply

Home Depot Faces Headwinds as Customers Shun Large-Scale Projects Amid Economic Uncertainty

Articles on this site are sourced from public networks or curated by AI for informational purposes only and do not represent BTCC’s views. Original rights belong to the respective authors. For copyright concerns, please contact [email protected]. BTCC assumes no liability for the accuracy, timeliness, or completeness of this information, and disclaims all liability arising from reliance on such content. This content is for reference only and should not be taken as investment, legal, or commercial advice.